#Precision medicine1

Biosensor reveals cancer-specific vulnerability in PRMT5

Researchers found that a metabolite change in some tumors makes the protein PRMT5 bind MTA instead of SAM. A new NanoBRET biosensor and a probe called CBH-002 measure drug binding to this cancer-specific form of PRMT5 in live cells.

Photo by National Cancer Institute, Unsplash